Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study

AUTOR(ES)

Franca, Suelene Aires, Carvalho, Carlos Roberto Ribeiro

FONTE

Brazilian Journal of Infectious Diseases

DATA DE PUBLICAÇÃO

2002-08

RESUMO

OBJECTIVES: Evaluation of the effectiveness, safety and tolerability of gatifloxacin in the treatment of outpatients with community-acquired pneumonia (CAP). STUDY DESIGN: A prospective, multicenter, non-comparative clinical study carried out in Brazil. Voluntary, unpaid physician participation contributed to an unbiased study design. PATIENTS: Adult outpatients with clinical diagnosis of CAP. REGIMEN: Gatifloxacin, 400 mg PO once daily for 7 to 14 days. STUDY PROCEDURES: Initial clinical assessment, at the first day of gatifloxacin therapy; final evaluation after 7 to 14 days of treatment. RESULTS: According to the physicians' assessments 97.3% of patients were cured or improved after gatifloxacin treatment. The incidence of adverse events was low and the most commonly reported events were nausea and dyspepsia. CONCLUSIONS: Gatifloxacin, 400 mg PO once daily for 7 to 14 days, is effective and safe in the treatment of patients with CAP.

Documentos Relacionados

• An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers
• Biomarkers in community-acquired pneumonia: A state-of-the-art review
• Community‐acquired pneumonia: doctors do not follow national guidelines
• Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study
• Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.